Key result
In hypertensive rats, combined treatment with an ARB and spironolactone significantly reduced left ventricular weight and cardiac fibrosis compared with either treatment alone (P<0.05).
Why the study?
Does the addition of an aldosterone antagonist to an ARB improve cardioprotective effects in hypertensive rats?
Does the addition of an aldosterone antagonist to an ARB improve cardioprotective effects in hypertensive rats?
The addition of an aldosterone antagonist to an ARB provides additive cardioprotective effects against target-organ damage in a hypertensive rat model.
BACKGROUND: There is increasing evidence to support the importance of blocking aldosterone to prevent target-organ damage in hypertension. We recently demonstrated an aldosterone breakthrough phenomenon during administration of an angiotensin type 1 receptor blocker (ARB). OBJECTIVE: To elucidate the pathophysiological significance of residual aldosterone by investigating the influence of the aldosterone antagonist on the cardioprotective effects of the ARB in hypertensive rats. METHODS: Injection vehicle alone, ARB (1.0 mg/kg per day candesartan by mouth), aldosterone antagonist (10 mg/kg per day spironolactone, subcutaneously), or combined treatment were administered to male stroke-prone spontaneously hypertensive rats for 24 weeks from the age of 4 weeks. Blood pressure, plasma angiotensin II and aldosterone concentrations, left ventricular weight, expression of type I and type III collagen mRNA, and histological findings were determined. RESULTS: In the ARB-treated group, aldosterone concentrations remained unchanged (1.10 +/- 0.20 nmol/l, compared with 1.17 +/- 0.46 nmol/l in the control group), whereas systolic blood pressure (178 +/- 9 mmHg), left ventricular weight (0.372 +/- 0.035 g/100 g body weight), expression of collagen mRNA, and cardiac interstitial and perivascular fibrosis all decreased significantly compared with the control group (systolic blood pressure: 222 +/- 10 mmHg, P < 0.05; left ventricular weight: 0.483 +/- 0.021 g/100 g body weight, P < 0.05). Although blood pressure (217 +/- 9 mmHg) and left ventricular weight (0.467 +/- 0.027 g/100 g body weight) remained unchanged in the group receiving spironolactone, the expression of both types of collagen mRNA and cardiac interstitial and perivascular fibrosis showed a significant decrease compared with the vehicle-treated group. In the rats receiving combined treatment with the ARB and spironolactone, left ventricular weight (0.352 +/- 0.005 g/100 g body weight, P < 0.05), expression of collagen mRNA, and cardiac interstitial and perivascular fibrosis all showed a further improvement compared with both the ARB and spironolactone groups. CONCLUSIONS: These results demonstrate that residual aldosterone has a significant impact on target-organ damage in hypertension, even during chronic administration of an ARB. The addition of an aldosterone antagonist has an advantage in facilitating the cardioprotective effects of ARBs.
No takes yet. Share an insight, caveat, or question.
Tanabe et al. (2004) studied Hypertension. Combined ARB (candesartan) and aldosterone antagonist (spironolactone) vs. Vehicle alone, ARB alone, or spironolactone alone was evaluated on Blood pressure, left ventricular weight, collagen mRNA expression, and cardiac fibrosis (p=<0.05). In hypertensive rats, combined treatment with an ARB and spironolactone significantly reduced left ventricular weight and cardiac fibrosis compared with either treatment alone (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Hypertension managementMore from Journal of Hypertension